Avantor, Inc.AVTR

Avantor, Inc. sells lab products and services to biopharma, diagnostics and applied markets, but the latest numbers read less like a growth flywheel and more like a cautious supply chain waiting for orders to re-accelerate. The company’s 10-Q for the quarter to 31 March 2026 shows revenues of $1.58 billion, up from the prior quarter, yet net income of $43.3 million and diluted EPS of only six cents. That return profile makes you question whether the customer stickiness touted in the pitch deck is showing up on the cash-flow line.

Operating income of $99.5 million looks solid, but the $58.7 million of operating cash flow is modest given the $810.3 million of inventory parked on the balance sheet. A $12.2 million increase in inventories in the quarter suggests either deliberate stock-building for expected demand or the world’s most expensive storage facility. Either way, it’s a working-capital story that investors are watching closely.

Cash and equivalents stood at $279.3 million at quarter-end, with $33.5 million of capex eating into cash generated from operations. The company’s liabilities total $6.07 billion against $5.59 billion of equity, leaving a leverage ratio that is neither terrifying nor trivial. The board’s decision to add a €250 million incremental term-loan priced at EURIBOR plus 250 basis points indicates a preference for optionality over immediate returns, a stance that reads like a banker’s nudge rather than a growth mandate.

The company’s Conflict Minerals Report sits in Exhibit 1.01 on its website, a compliance artefact that few customers cite when choosing a lab supplier. Meanwhile, the employment letter for VWR International’s Corey Walker, now ensconced at Avantor, confirms the continuing reliance on key personnel whose departure could disrupt customer relationships. The agreement explicitly bars assignment, underlining how personal the company’s customer and supplier connections remain.

For now, Avantor is a large, cash-generative industrial distributor with a balance sheet built for prudence rather than pizzazz. The tension is whether the next upturn in biopharma R&D will translate into margin expansion or merely more inventory on the floor. Until that happens, the stock trades less on growth and more on the reliability of its working-capital discipline and the durability of its customer relationships.